FINWIRES · TerminalLIVE
FINWIRES

研究快報:CFRA維持對Neurocrine Biosciences Inc.股票的持有評等。

By

-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師的觀點總結如下:我們將目標股價從167美元上調至175美元,基於16.0倍的2027年每股收益預期,該市盈率低於NBIX過去五年21.1倍的平均預期市盈率。我們將2026年每股盈餘預期從8.86美元上調至8.94美元,並將2027年每股盈餘預期從9.42美元上調至10.92美元。在NBIX公佈了強勁的2026年第一季業績後,我們繼續看好其股票。該季度淨產品銷售額首度突破8億美元,較去年同期成長44%。這項業績主要得益於Ingrezza的持續成長和Crenessity的成功上市。我們對NBIX擬以29億美元收購Soleno Therapeutics的交易也感到鼓舞,該交易預計將於2026年第二季完成,屆時Vykat XR將加入NBIX的商業產品組合,並增強其成長前景。我們認為,該公司正成功推進其豐富的產品線,並計劃在年內啟動六項新的I期臨床試驗和四項新的II期臨床試驗。

Related Articles

Mining & Metals

Earnings Flash (SCR.TO) Strathcona Reports Q1 Production of 116,542 boe/d (99.7% Liquids); Free Cash Flow of $47M ($0.22 / share)

$SCR.TO
Equities

Tenaris Fiscal Q1 Earnings, Revenue Rise

Tenaris (TS) reported fiscal Q1 earnings late Wednesday of $1.07 per American depository share, up from $0.94 a year earlier.Analysts polled by FactSet expected $0.89.Net sales for the quarter ended March 31 rose to $3.10 billion from $2.92 billion a year earlier.Analysts surveyed by FactSet expected $2.99 billion.For Q2, the company said it expects sales will be affected by lower shipments in the Middle East.

$TS
Research

Research Alert: American Homes 4 Rent Reports Mixed Results In Q1 2026

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:AMH delivered Q4 2025 FFO of $0.47 per share, in line with consensus, while revenue of $455M missed estimates despite 4.2% growth driven by higher rental rates. Average occupancy declined 30 bps to 95.0% and blended lease rates of +2.8% decelerated from 3.6% in Q3, signaling weakening pricing power in a challenging rental market. Management significantly lowered 2026 core NOI growth guidance to just 1.0%-3.0%, down from beginning 2025 expectations, citing economic uncertainties. The trust maintains a strong balance sheet with $5.2B total debt, no maturities until 2028, and 8.5-year average maturity. AMH plans $500M-$600M in property acquisitions and $150M-$250M in development for 2026, while executing $115M in share repurchases. We view the disappointing guidance and slowing lease growth as signs of mounting operational headwinds, though the unencumbered balance sheet and disciplined capital allocation provide some stability in the near term.

$AMH